REFERENCES
Scully LJ, Clarke D, Barr RJ: Diclofenac induced hepatitis: 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 38:744-751, 1993
Sinclair SB, Greig PD, Blendis LM, Abecassis M, Roberts EA, Phillips MJ, Cameron R, Levy GA: Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report. J Clin Invest 84:1063-1069, 1989
Sheener P, Sinclair S, Greig P, Logan A, Blendis LM, Levy G: A randomized control trial of prostaglandin E2 (PGE2) in the treatment of fulminant hepatic failure. Hepatology 16:88A, 1992
O'Brien CB, Henzel BS, Naji A, Long WB: Prostaglandin E1 infusion improve survival of patients with fulminant hepatic failure. Gastroenterology 102:A862, 1992
Sherlock S: The spectrum of hepatotoxicity due to drugs. Lancet 2:440-444, 1986
Park BK, Coleman JW, Kitteringham NR: Drug disposition and drug hypersensitivity. Biochem Pharmacol 36:581-590, 1987
Quiroga J, Prieto J: Liver cytoprotection by prostaglandins. Pharmacol Ther 58:67-92, 1993
Cattral MS, Altraif I, Greig PD, Blendis L, Levy GA: Toxic effect of intravenous and oral prostaglandin E therapy in patient with liver disease. Am J Med 97:369-373, 1994
Rights and permissions
About this article
Cite this article
Ohana, M., Hajiro, K., Takakuwa, H. et al. Letter to the Editor. Dig Dis Sci 42, 2031–2032 (1997). https://doi.org/10.1023/A:1018802014177
Issue Date:
DOI: https://doi.org/10.1023/A:1018802014177